Pharmaceuticals

FDA Approves Ascendis Pharma’s Yorbipath as First Treatment for Adults with Hypoparathyroidism

bexib
By bexib 0 Min Read

Yorbipath is designed to deliver parathyroid hormone over a 24-hour period to patients with hypoparathyroidism.

You Might Also Like

CVS Caremark Issues Statement on Role of PBMs

Study finds cholesterol-lowering drug reduces risk of diabetic retinopathy

IDN Trends, Insights, and Strategies Every Manufacturer Should Know

Weight-loss drug shortages prompt multiple companies to launch shortage-tracking platform

Big Pharma’s Most Improved Medicines: A New Generation of Blockbuster Products

Share This Article
Previous Article SEO tools that analyze HTML headings
Next Article Remain bullish on dollar, sell on EUR/USD rise – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Fifth Third expands branch network and doubles technology capabilities
Banking
KeyBank increases technology spending by 10% in 2025
Banking
Trump’s fintech appointees could influence regulation
Banking
10 books for better communication
Retail & E-commerce